Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.

Proceedings of the National Academy of Sciences of the United States of America - 17 Jul 2001

Taneja S, MacGregor J, Markus S, Ha S, Mohr I

Abstract excerpt

Replication-competent, attenuated herpes simplex virus-1 (HSV-1) derivatives that contain engineered mutations into the viral gamma 34.5 virulence gene have been used as oncolytic agents. However, as attenuated mutants often grow poorly, they may not completely destroy some tumors and surviving cancer cells simply regrow. Thus, although HSV-1 gamma 34.5 mutants can reduce the growth of human tumor xenografts in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Herpesvirus 1, Human

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Neoplasms, Experimental

Share to Prostatic Neoplasms

Share to Tumor Cells, Cultured

Share to Viral Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 11438715
DOI: 10.1073/pnas.161011798
PMCID: PMC37516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.PMID 11438715Read ↗

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?Semantic proximity Read ↗

Genetic Modifications That Expand Oncolytic Virus PotencySemantic proximity Read ↗

Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.Semantic proximity Read ↗

First-in-class small molecule potentiators of cancer virotherapySemantic proximity Read ↗

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.Semantic proximity Read ↗

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachmentSemantic proximity Read ↗

Synthetic Genome Shuffling of Poxviruses through Yeast for Next-Generation Oncolytic PlatformsSemantic proximity Read ↗

Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.Semantic proximity Read ↗

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.